Mu 1 Opioid Receptor Genotyping (OPRM1)
Whole blood or buccal swabs
5 mL of whole blood or four buccal swabs
3 mL of whole blood or four buccal swabs
Lavender-stopper (EDTA) tube or paper envelope for dried buccal swabs
Maintain at room temperature or refrigerate
Cause for Rejection
Hemolyzed specimen; quantity not sufficient
General Purpose and Use
Opioid agonists, such as morphine, hydromorphone, and oxymorphone, exert their analgesic properties via stimulation of the mu-1 opioid receptor. Analgesic efficacy of mu-acting drugs has been linked to the 118A>G single nucleotide polymorphism (SNP) of OPRM1, the gene encoding the mu-1 receptor. The frequency of the variant G allele varies from 10% to 48% depending on the population studied. Studies show that patients carrying the GG (homozygous variant) genotype require much higher opioid doses to achieve pain relief. Additionally, patients with the AA genotype display higher relapse rates with respect to naltrexone treatment for alcohol dependence.
Other variants of the OPRM1 gene that are not detected in this assay may influence drug response. All factors should be considered as part of the overall patient management strategy.
Real-time polymerase chain reaction with fluorescence detection.
For a PDF version, click here.